Equillium, Inc. · NASDAQ:EQ
Equillium — Investor Presentation (February 2023)
34 slides from Equillium's investor presentation, February 2023
Slide 1: Corporate Presentation
Corporate Presentation February 2023
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements about Equillium, Inc. (the Actual results or events could differ materially from the plans, intentions and “Company”). In some cases, you can identify forward-looking statements by expectations disclosed or implied in t
Slide 3: Equillium Snapshot: Resetting Balance, Restoring Health
Equillium Snapshot First-in-Class Immunology Assets Resetting Balance, Novel Multi-Cytokine Restoring Health Inhibitors Partnership for itolizumab Leveraging a deep understanding of immunology Multiple to pioneer new therapies for Clinical Near-term Stage Catalysts severe autoimmune and Programs Cas
Slide 4: Diversified Pipeline of First-In-Class Immunology Assets
Diversified Pipeline of First-In-Class Immunology Assets Drugs Indication & Delivery Pre-Clinical Phase 1 Phase 2 Phase 3 Partners Status & Designations EQ101 alopecia areata • Phase 2 study actively enrolling in AA IL-2/9/15 intravenous • FDA/EMA Orphan Drug Designations & antagonist (subcutaneous
Slide 5: Ono Pharmaceutical: Option & Asset Purchase Agreement
Ono Pharmaceutical: Option & Asset Purchase Agreement Equillium receives upfront payment and full funding for itolizumab R&D in exchange for Ono exclusive option to purchase Equillium’s rights to itolizumab Upfront payment: $26.0M Option exercise payment: $37.1M Milestone payments: $101.4M Total pot
Slide 6: EQ101 & EQ102 Targeted Multi-Cytokine Inhibitors
Proprietary Product Discovery Platform EQ101 & EQ102 EQ101: alopecia areata Targeted Multi- Cytokine Inhibitors EQ102: celiac disease 6
Slide 7: Discovery Platform – Multi-cytokine Inhibitors
Discovery Platform – Multi-cytokine Inhibitors Novel product platform addresses the limitations of single-target biologics and broadly immunosuppressive therapies (e.g. JAKi) through peptide-based multi-cytokine inhibition • Targeting validated biological and disease pathways • Leveraging in-house e
Slide 8: Optimized Modality Compared to mAbs and JAK Inhibitors
Optimized Modality Compared to mAbs and JAK Inhibitors Multi-cytokine inhibition at the receptor level without the broad immuno-suppression and off target safety liabilities of JAK inhibitors mAb JAK inhibitor EQ Peptides Inhibits one cytokine Inhibits 50+ cytokines Inhibits selective cytokines Insu
Slide 9: EQ101: A First-in-class Tri-Specific Cytokine Inhibitor
EQ101: A First-in-class Tri-Specific Cytokine Inhibitor Inhibition of IL-2, IL-9, and IL-15 biology by EQ101 translates from preclinical models into humans • IL-2 and IL-15 are important to CD8 and NK cell biology, while IL-9 EQ101 - Pegylated peptide contributes to inflammation in the skin • EQ101
Slide 10: EQ101 inhibits IL-2/9/15 similarly to JAK inhibition in ATL model
EQ101 inhibits IL-2/9/15 performing similarly to JAK inhibition in IL-15 driven ATL model IL-2, IL-9, and IL-15 are overexpressed in adult T cell leukemia (ATL) and cutaneous T cell lymphoma (CTCL) where they drive cancer cell proliferation and increased inflammation in the skin1,2,3,4,5 Blocking IL
Slide 11: Phase 1/2 Proof-of-Concept Study of EQ101 in CTCL Patients
Phase 1/2 Proof-of-Concept Study of EQ101 in CTCL Patients Clinically validated with favorable safety profile, Phase 2/3 ready to address multiple indications with significant unmet medical need Phase 1/2 MAD study in CTCL • Heavily pre-treated population (median of 5 prior systemic treatments) • Do
Slide 12: EQ101 is Clinically Validated in Severe Dermatological Disease
EQ101 is Clinically Validated in Severe Dermatological Disease EQ101 reduces IL-2 & IL-15 dependent cells and inflammation with improvements in skin lesions and overall response rate (ORR) comparing favorably with benchmark drugs MAVORIC trial evaluating mogamulizumab and vorinostat provides the mos
Slide 13: Alopecia Areata Overview
Alopecia Areata Overview Alopecia areata: an autoimmune disease characterized by T-cell infiltration into the hair follicle resulting in non-scarring hair loss 300,000 Moderate to severe patients in the U.S.1 JAK Inhibitor Other Of alopecia areata patients report an 84% JAK Inhibitors Alternative Me
Slide 14: Alopecia Areata - Pathophysiology
Alopecia Areata - Pathophysiology The targets for EQ101 inhibition (IL-2, IL-9 and IL-15) are key drivers of disease leading to a cycle of increased IFN-g production and loss of hair follicle in alopecia areata patients Activated T cells secrete IFN-g IFN-g binds to receptor on hair follicle Hair fo
Slide 15: EQ101 Inhibits Immune-Mediated Hair Loss in a Mouse Model
EQ101 Inhibits Immune-Mediated Hair Loss in a Mouse Model EQ101 is more effective than ruxolitinib at hair regrowth and suppression of cytotoxic CD8+ T- cells in humanized alopecia model EQ101 Improves Hair Regrowth EQ101 Reduces CD8+ Cytotoxic T-cell Activation Marker NKG2D 2 mg/kg IV 2x/week x 2 w
Slide 16: EQ101 Provides Complete Cytokine-Mediated Signal Inhibition
EQ101 Provides Complete Cytokine-Mediated Signal Inhibition Effect of JAK inhibitors on cytokine signaling is broad yet incomplete, whereas EQ101 can inhibit multiple downstream pathways for a more potent suppression of cytokine signaling EQ101 IL-2 IL-2 JAKi - IL-2 +EQ101 - IL-2 +ruxolitinib P ERK
Slide 17: Phase 2 Study of EQ101 in Adults With Moderate to Severe AA
Phase 2 Study of EQ101 in Adults With Moderate to Severe AA Phase 2 open label study to evaluate safety and efficacy after 24 weeks of treatment Primary Objective • Evaluate the safety and tolerability of EQ101 in adult subjects with moderate to severe alopecia areata over 24 Screening Treatment Per
Slide 18: Alopecia Areata Benchmark – Deuruxolitinib Phase 3
Alopecia Areata Benchmark – Deuruxolitinib Phase 3 • Negligible placebo response in alopecia areata patients enables clear signal detection in single-arm trials by week 24 18 Source: Concert Pharmaceuticals corporate presentation
Slide 19: Opportunity for High-Value Dermatology Franchise for EQ101
Opportunity for High-Value Dermatology Franchise for EQ101 EQ101 is positioned as an optimized alternative to JAKi for multiple dermatology indications 2023 Projected WW 2028 Projected WW Sales Mogamulizumab Sales1 for JAK inhibitors1 Unmet need for safe and effective therapies for early-stage cutan
Slide 20: EQ102: A First-in-class Dual Cytokine Inhibitor for GI Inflammation
EQ102: A First-in-class Dual Cytokine Inhibitor for GI Inflammation EQ102 targets natural biological synergy of IL-15 and IL-21 modulating both T and B cell biology • IL-15 and IL-21 work together driving GI inflammation in celiac EQ102 - Pegylated peptide disease and inflammatory bowel disease pati
Slide 21: Celiac Disease Overview
Celiac Disease Overview Celiac disease: a complex autoimmune disease characterized by the overproduction of 3,000,000 Celiac disease patients in the U.S.1, 2 inflammatory cytokines, intra-epithelial T cell infiltration into the intestine, and tissue damage in response to gluten consumption Of patien
Slide 22: Dual Action Provides Advantage in Treating Celiac Disease
Dual Action Provides Advantage in Treating Celiac Disease Elevated levels of IL-15 & IL-21 synergistically drive the T and B cell responses culminating in tissue damage in celiac patients – maximal effect achieved only when inhibiting both cytokines Autoantibodies EQ102 or two mAbs inhibit IL-15 & I
Slide 23: EQ102: A Novel, Targeted Dual Cytokine Inhibitor for GI Disease
EQ102: A Novel, Targeted Dual Cytokine Inhibitor for GI Disease • Potential to be a differentiated asset in the GI space addressing key inflammatory drivers IL-15 and IL-21 • Lead indication: celiac disease • IL-15 inhibition alone failed to prevent mucosal injury in response to gluten challenge, hi
Slide 24: EQ001 Itolizumab
Ono Pharmaceutical Partnership EQ001 Acute Graft-Versus-Host Disease Itolizumab Lupus / Lupus Nephritis 24
Slide 25: Clinically Meaningful Complete Responses in First-line High-Risk aGVHD
Clinically Meaningful Complete Responses in First-line High-Risk* aGVHD 100% Itolizumab showing improved response at Day 29 (itolizumab Itolizumab + Steroids (≤3 days on steroids) + steroids) CR/ORR Response Rate at Day 29 80% GRAVITAS-301 67% 0.4 mg/kg, N=4 50%/50% (steroids alone) ORR MacMillan 0.
Slide 26: EQUATOR Study: First-line Treatment of High-Risk aGVHD
EQUATOR Study: First-line Treatment of High-Risk aGVHD Phase 3 randomized, double-blind, global pivotal study of itolizumab in ~ 200 patients Itolizumab: IV 1.6 mg/kg loading dose followed by 0.8 mg/kg Q2W x 6 doses (n=100) Primary Outcome Grade III-IV patients & • Complete Response Rate at Day 29 G
Slide 27: EQUALISE Study: Systemic Lupus Erythematosus & Lupus Nephritis
EQUALISE Study: Systemic Lupus Erythematosus & Lupus Nephritis Phase 1b open-label study: enrolling Type B (LN patients) Primary Objective Cohort 1: 0.4 mg/kg Type B Type A Type A & B patients with • Assess the safety and tolerability of patients with active LN requiring itolizumab in subjects with
Slide 28: EQUALISE LN Patients: Clinical Responses at 12 & 28 Weeks
EQUALISE LN Patients: Clinical Responses at 12 & 28 Weeks 18% 17% 17% Greater ORR achieved by 12 and 28 ORR: 45% weeks than is expected with standard 27% ORR: 25% of care alone 33% ORR: 67% 83% 25% Legend 33% Complete Response: > 50% UPCR reduction and < 0.5 g/g 56% Complete Response: > 50% UPCR red
Slide 29: Corporate
an eQuillium HUM Corporate
Slide 30: Accomplished Executive Leadership
Accomplished Executive Leadership Christine Bruce Steel, CFA Steve Connelly, PHD Zedelmayer CHIEF EXECUTIVE OFFICER CHIEF SCIENTIFIC OFFICER CHIEF OPERATING OFFICER BioMed Ventures • Rincon BioMed Ventures • aTyr Pharma Amylin • Amgen • Ligand Anaphore • Ambit The Scripps Research Institute Jason Ke
Slide 31: Equillium Intellectual Property & Regulatory Exclusivity
Equillium Intellectual Property & Regulatory Exclusivity gc-Cytokine Family/EQ101 Compositions and Methods gc, IL-6, IL-17 Cytokine Families Compositions/Methods Cytokine Technologies EQ102 Compositions/Methods 6 patent families 30 issued patents 43 applications pending Orally-Delivered Peptides Com
Slide 32: Equillium Financial Overview
Equillium Financial Overview Key Financial Metrics Total Cash and Investments (as of September 30, 2022) $44.5M * $13.1M Well capitalized to reach Q3 2022 Operating Cash Burn multiple data catalysts Outstanding Debt Principal (as of September 30, 2022) $10.0M Lean operating model and disciplined spe
Slide 33: Catalysts & Milestones
Catalysts & Milestones EQ101 Data from Phase 2 study in alopecia areata 2023 EQ102 Data from Phase 1 study in healthy volunteers and patients with celiac disease 2023 EQUALISE Topline data from Phase 1b EQUALISE study Type B patients – lupus nephritis mid-2023 33
Slide 34: Thank you
Thank you www.equilliumbio.com